Fundamentaly I feel Glanmark life is better as compared to Rolex at current valuation. But GMP depends upon demand/supple and many other factors. But still I feel ROI for NII will be better in Glanmark.
π China+1 strategy: In 2020, according to the DRHP, an estimated 40% of all factories in China have shut down -resulting in supply disruptions and higher costs. This has caused several major pharma countries to reconsider and reshuffle their API import sources.
Manufacturing: 3 of the 4 plants are USFDA approved;
Future CAPEX plans:
Plans to utilize ~Rs 1.53bn from the IPO proceeds towards CAPEX; includes enhancing the production capacity of Ankleshwar (FY22) and Dahej (in FY22&23) facilities to an aggregate annual capacity of 200KL.
Leadership in Select High Value, Non-Commoditized APIs in Chronic Therapeutic Areas: Key products in the companyβs portfolio include Atovaquone, Perindopril, Adapalene, and Zonisamid